Show simple item record

dc.contributor.authorAgbuduwe, Charles
dc.contributor.authorIqbal, Gulnaz
dc.contributor.authorCairns, David
dc.contributor.authorMenzies, Tom
dc.contributor.authorDunn, Janet
dc.contributor.authorGregory, Walter
dc.contributor.authorKaiser, Martin
dc.contributor.authorOwen, Roger
dc.contributor.authorPawlyn, Charlotte
dc.contributor.authorChild, J. Anthony
dc.contributor.authorDavies, Faith
dc.contributor.authorMorgan, Gareth J.
dc.contributor.authorJackson, Graham H.
dc.contributor.authorDrayson, Mark
dc.contributor.authorBasu, Supratik
dc.date.accessioned2023-02-28T10:34:41Z
dc.date.available2023-02-28T10:34:41Z
dc.date.issued2022-07-05
dc.identifier.citationAgbuduwe, C., Iqbal, G., Cairns, D.A. et al. (2022) Clinical Characteristics and Outcomes of IgD Myeloma: Experience across UK National Trials. Blood Advances, 6 (17). pp. 5113-5123.en
dc.identifier.issn2473-9529en
dc.identifier.pmid35790108 (pubmed)
dc.identifier.doi10.1182/bloodadvances.2022007608en
dc.identifier.urihttp://hdl.handle.net/2436/625127
dc.description© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.en
dc.description.abstractImmunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes of patients with IgD myeloma from UK phase 3 myeloma trials analyzed in 2 groups: old (1980-2002) and recent (2002-2016) clinical trials, based on the time of adoption of novel myeloma therapies. Patients with IgD myeloma comprised 44 of 2789 (1.6%) and 70 of 5773 (1.2%) of the old and recent trials, respectively. Overall, IgD myeloma was associated with male predominance, low-level paraproteinemia (,10g/L), and l light chain preference. The frequency of ultra-high-risk cytogenetics was similar in IgD myeloma compared with other subtypes (4.3% vs 5.3%, P . .99). Despite the old trial series being a younger group (median age: 59 vs 63 years, P 5 .015), there was a higher frequency of bone lesions, advanced stage at diagnosis, worse performance status, and severe renal impairment compared with the recent trials. Furthermore, the early mortality rate was significantly higher for the old trial series (20% vs 4%, P 5 .01). The overall response rate following induction therapy was significantly higher in the recent trials (89% vs 43%, P, .0001), and this was consistent with improved median overall survival (48 months; 95% confidence interval [CI] 35-67 months vs 22 months; 95% CI, 16-29 months). Survival outcomes for IgD myeloma have significantly improved and are now comparable to other myeloma types because of earlier diagnosis, novel therapies, and improved supportive care.en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherAmerican Society of Hematologyen
dc.relation.urlhttps://ashpublications.org/bloodadvances/article/6/17/5113/485790/Clinical-characteristics-and-outcomes-of-IgDen
dc.subjectclinical trialsen
dc.subjectLymphoid Neoplasiaen
dc.subject.meshHumans
dc.subject.meshMultiple Myeloma
dc.subject.meshParaproteinemias
dc.subject.meshImmunoglobulin D
dc.subject.meshAge Factors
dc.subject.meshSex Factors
dc.subject.meshMiddle Aged
dc.subject.meshFemale
dc.subject.meshImmunoglobulin lambda-Chains
dc.subject.meshMale
dc.subject.meshUnited Kingdom
dc.titleClinical characteristics and outcomes of IgD myeloma: experience across UK national trialsen
dc.typeJournal articleen
dc.identifier.eissn2473-9537
dc.identifier.journalBlood Advancesen
dc.date.updated2023-02-27T10:38:58Z
dc.contributor.institutionUCL Cancer Institute, London, United Kingdom.
pubs.place-of-publicationUnited States
dc.date.accepted2022-06-22
rioxxterms.funderCancer Research UKen
rioxxterms.identifier.projectA25447en
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2023-02-28en
dc.source.volume6
dc.source.issue17
dc.source.beginpage5113
dc.source.endpage5123
dc.description.versionPublished version
refterms.dateFCD2023-02-28T10:34:32Z
refterms.versionFCDVoR
refterms.dateFOA2023-02-28T10:34:42Z


Files in this item

Thumbnail
Name:
Clinical characteristics and ...
Size:
1.349Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/